

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Antibody-Drug Conjugates for Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Presented data from the Phase III DESTINY-Breast11 study comparing trastuzumab deruxtecan (T-DXd) followed by paclitaxel/trastuzumab/pertuzumab (THP) before surgery to standard neoadjuvant therapy for high-risk HER2-positive localized breast cancer reported which efficacy outcome?**

 - A numerical but nonsignificant improvement in pathologic complete response (pCR) rate with T-DXd followed by THP
 - A statistically significant improvement in pCR rate with T-DXd followed by THP**
 - A numerical but nonsignificant improvement in overall survival (OS) with T-DXd followed by THP
 - A statistically significant improvement in OS with T-DXd followed by THP
- 2. What was the approximate reduction in risk of disease progression or death with T-DXd and pertuzumab in comparison to THP as first-line therapy for patients with advanced HER2-positive breast cancer in the Phase III DESTINY-Breast09 trial?**

 - 10%
 - 24%
 - 44%**
- 3. Recently presented data from the Phase III TROPION-Breast02 study suggest that datopotamab deruxtecan as a component of first-line therapy improves OS and progression-free survival (PFS) for patients with metastatic triple-negative breast cancer in which of the following settings?**

 - In combination with durvalumab for PD-L1-positive disease
 - As monotherapy for patients for whom immunotherapy is not an option**
 - Both in combination with durvalumab for PD-L1-positive disease and as monotherapy for patients for whom immunotherapy is not an option
 - None of the above
- 4. How did the Phase III ASCENT-03 and TROPION-Breast02 trials approach crossover among patients in the control arm who experienced disease progression on chemotherapy?**

 - Both allowed crossover
 - Neither allowed crossover
 - ASCENT-03 allowed crossover and TROPION-Breast02 did not**
 - TROPION-Breast02 allowed crossover and ASCENT-03 did not
- 5. Recently presented findings from the Phase III ASCENT-03 study evaluating first-line sacituzumab govitecan versus chemotherapy for patients with metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors include which of the following outcomes?**

 - Inferior PFS with sacituzumab govitecan
 - Numerical but nonsignificant improvement in PFS with sacituzumab govitecan
 - Statistically significant improvement in PFS with sacituzumab govitecan**